CoChat

Effect of Oral Digoxin in High-Risk Heart Failure Patients: A Pre-Specified Subgroup Analysis of the DIG Trial

Open access
Gheorghiade, Mihai, Patel, Kanan, Filippatos, Gerasimos, Anker, Stefan D., van Veldhuisen, Dirk J., Cleland, John G.F., Metra, Marco, Aban, Inmaculada B., Greene, Stephen J., Adams, Kirkwood F., McMurray, John J.V., Ahmed, Ali · 2013 · European Journal of Heart Failure
Cited by 115

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Aims: In the Digitalis Investigation Group (DIG) trial, digoxin reduced mortality or hospitalization due to heart failure (HF) in several pre-specified high-risk subgroups of HF patients, but data on protocol-specified 2-year outcomes were not presented. In the current study, we examined the effect of digoxin on HF death or HF hospitalization and all-cause death or all-cause hospitalization in high-risk subgroups during the protocol-specified 2 years of post-randomization follow-up. Methods and results: In the DIG trial, 6800 ambulatory patients with chronic HF, normal sinus rhythm, and LVEF ≤45% (mean age 64 years, 26% women, 17% non-whites) were randomized to receive digoxin or placebo. The three high-risk groups were defined as NYHA class III–IV symptoms (n = 2223), LVEF <25% (n = 2256), and cardiothoracic ratio (CTR) >55% (n = 2345). In all three high-risk subgroups, compared with patients in the placebo group, those in the digoxin group had a significant reduction in the risk of the 2-year composite endpoint of HF mortality or HF hospitalization: NYHA III–IV [hazard ratio (HR) 0.65; 95% confidence interval (CI) 0.57–0.75; P < 0.001], LVEF <25% (HR 0.61; 95% CI 0.53–0.71; P < 0.001), and CTR >55% (HR 0.65; 95% CI 0.57–0.75; P < 0.001). Digoxin-associated HRs (95% CI) for 2-year all-cause mortality or all-cause hospitalization for subgroups with NYHA III–IV, LVEF <25%, and CTR >55% were 0.88 (0.80–0.97; P = 0.012), 0.84 (0.76–0.93; P = 0.001), and 0.85 (0.77–0.94; P = 0.002), respectively. Conclusions: Digoxin improves outcomes in chronic HF patients with NYHA class III–IV, LVEF <25%, or CTR >55%, and should be considered in these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurjhf/hft010

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 115

Metadata

Authors
Gheorghiade, M., Patel, K., Filippatos, G., Anker, S. D., van Veldhuisen, D. J., Cleland, J. G. F., Metra, M., Aban, I. B., Greene, S. J., Adams, K. F., McMurray, J. J. V., & Ahmed, A.
Venue
European Journal of Heart Failure
Published
2013-05-01
Volume
15
Issue
5
Pages
551-559
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2126847055
Cited by
115
References
11
FWCI
8.90
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Oral Digoxin in High-Risk Heart Failure Patients: A Pre-Specified Subgroup Analysis of the DIG Trial. https://app.cochat.ai/papers/10.1093/eurjhf/hft010
The paper
Gheorghiade, M., Patel, K., Filippatos, G., Anker, S. D., van Veldhuisen, D. J., Cleland, J. G. F., Metra, M., Aban, I. B., Greene, S. J., Adams, K. F., McMurray, J. J. V., & Ahmed, A. (2013). Effect of Oral Digoxin in High-Risk Heart Failure Patients: A Pre-Specified Subgroup Analysis of the DIG Trial. European Journal of Heart Failure. https://doi.org/10.1093/eurjhf/hft010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.